Belite Bio Inc (BLTE) said that it has appointed Hendrik Scholl as the Chief Medical Officer of the company, effective immediately.Scholl currently serves as President of the European Vision Institute as well as Chairman of the largest clinical research network in ophthalmology in Europe, EVICR.net, and its Expert Committee on Retinal Dystrophies.

贝利特生物公司（BLTE）表示，已任命亨德里克·斯科尔（HendrikScholl）为该公司首席医疗官，立即生效。Scholl目前担任欧洲视觉研究所（European Vision Institute）主席，也是欧洲最大的眼科临床研究网络EVICR.net及其视网膜营养不良专家委员会的主席。

He is also the Founder and President of the Swiss Association for Research in Vision and Ophthalmology (ARVO-SWISS). .

他还是瑞士视觉和眼科研究协会（ARVO-Swiss）的创始人和主席。

Recently, Scholl served as Professor of Ophthalmology and Endowed Chair at the Wilmer Eye Institute of Johns Hopkins University Medical School. At the Johns Hopkins Hospital, he was the Head of the Retinal Degeneration Clinic and the Director of the Visual Neurophysiology Service. For the Wilmer Eye Institute, he also served as the Co-director of the Johns Hopkins Center for Stem Cells and Ophthalmic Regenerative Medicine.

最近，斯科尔担任约翰·霍普金斯大学医学院威尔默眼科研究所眼科教授和捐赠主席。在约翰·霍普金斯医院，他是视网膜变性诊所的负责人和视觉神经生理学服务的主任。在威尔默眼科研究所，他还担任约翰·霍普金斯干细胞和眼科再生医学中心的联合主任。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In August 2024

2024年8月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In June 2024

2024年6月美国食品和药物管理局决定生物技术股

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股